

Josep Lupon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4301890/publications.pdf>

Version: 2024-02-01

212
papers

6,145
citations

66343

42
h-index

102487

66
g-index

233
all docs

233
docs citations

233
times ranked

7211
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Determinants and Prognosis of Left Ventricular Reverse Remodelling in Non-Ischemic Dilated Cardiomyopathy. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 20.	1.6	2
2	Cause of Death in Heart Failure Based on Etiology: Long-Term Cohort Study of All-Cause and Cardiovascular Mortality. <i>Journal of Clinical Medicine</i> , 2022, 11, 784.	2.4	4
3	Urinary NGAL in acute heart failure revisited: the game is not over yet. <i>International Journal of Cardiology</i> , 2022, 357, 113-114.	1.7	2
4	Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond. <i>Cardiac Failure Review</i> , 2022, 8, e12.	3.0	19
5	Circulating levels and prognostic cutoffs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure. <i>ESC Heart Failure</i> , 2022, 9, 2084-2095.	3.1	15
6	Nutritional Status According to the GLIM Criteria in Patients with Chronic Heart Failure: Association with Prognosis. <i>Nutrients</i> , 2022, 14, 2244.	4.1	4
7	A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy. <i>Cancers</i> , 2022, 14, 2941.	3.7	4
8	Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes. <i>Journal of Clinical Medicine</i> , 2022, 11, 3558.	2.4	5
9	Prognostic value of lung ultrasound in chronic stable ambulatory heart failure patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 862-869.	0.6	4
10	Association between right-sided cardiac function and ultrasound-based pulmonary congestion on acutely decompensated heart failure: findings from a pooled analysis of four cohort studies. <i>Clinical Research in Cardiology</i> , 2021, 110, 1181-1192.	3.3	26
11	Impact of prescription patterns of antithrombotic treatment on atrial fibrillation-related ischemic stroke. <i>Current Medical Research and Opinion</i> , 2021, 37, 357-365.	1.9	5
12	Thirst and factors associated with frequent thirst in patients with heart failure in Spain. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2021, 50, 86-91.	1.6	9
13	Soluble Nephilysin and Corin Concentrations in Relation to Clinical Outcome in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 85-95.	4.1	12
14	Meteorin-like/Meteorin- β^2 protects heart against cardiac dysfunction. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	33
15	Preload dependence of pulmonary haemodynamics and right ventricular performance. <i>Clinical Research in Cardiology</i> , 2021, 110, 591-600.	3.3	1
16	Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, . .	0.6	3
17	Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data. <i>Clinical Research in Cardiology</i> , 2021, 110, 1280-1291.	3.3	20
18	The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations. <i>Scientific Reports</i> , 2021, 11, 5940.	3.3	2

#	ARTICLE	IF	CITATIONS
19	Heart failure is ejection fraction in motion. <i>European Journal of Heart Failure</i> , 2021, 23, 564-566.	7.1	4
20	Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?. <i>PLoS ONE</i> , 2021, 16, e0249674.	2.5	1
21	Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 3014-3025.	3.1	11
22	Thirst distress in outpatients with heart failure in a Mediterranean zone of Spain. <i>ESC Heart Failure</i> , 2021, 8, 2492-2501.	3.1	7
23	Decoding empagliflozin's molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence. <i>Scientific Reports</i> , 2021, 11, 12025.	3.3	23
24	Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review. <i>European Journal of Heart Failure</i> , 2021, 23, 1445-1457.	7.1	60
25	NT-proBNP for Risk Prediction in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 653-663.	4.1	20
26	Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018. <i>Scientific Reports</i> , 2021, 11, 732.	3.3	14
27	A new option for monitoring heart failure. First experience in Spain with CardioMEMS. <i>Medicina Clínica</i> , 2021, 156, 26-28.	0.6	1
28	1H-magnetic resonance spectroscopy lipoprotein profile in patients with chronic heart failure versus matched controls. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, , .	0.6	1
29	Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease. <i>Journal of Cardiovascular Medicine</i> , 2021, Publish Ahead of Print, 28-36.	1.5	1
30	How a large registry can explain pathophysiology: The case of anemia in the heart failure syndromes. <i>International Journal of Cardiology</i> , 2020, 298, 72-73.	1.7	0
31	CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction. <i>American Journal of Medicine</i> , 2020, 133, 370-380.e4.	1.5	58
32	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T. <i>European Journal of Heart Failure</i> , 2020, 22, 2078-2088.	7.1	26
33	Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction: a pilot study. <i>ESC Heart Failure</i> , 2020, 7, 118-123.	3.1	14
34	Myocardial interstitial fibrosis in the era of precision medicine. Biomarker-based phenotyping for a personalized treatment. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 248-254.	0.6	4
35	Tendencies in cause of death in patients with chronic heart failure and depressed systolic function. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 783-784.	0.6	0
36	Sacubitril/Valsartan as Antifibrotic Drug. <i>Journal of the American College of Cardiology</i> , 2020, 76, 515-517.	2.8	4

#	ARTICLE	IF	CITATIONS
37	Trends in Short- and Long-Term ST-Segment Elevation Myocardial Infarction Prognosis Over 3 Decades: A Mediterranean Population-Based ST-Segment Elevation Myocardial Infarction Registry. <i>Journal of the American Heart Association</i> , 2020, 9, e017159.	3.7	16
38	Short- and Long-Term Mortality Trends in STEMI-Cardiogenic Shock over Three Decades (1989–2018): The Ruti-STEMI-Shock Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 2398.	2.4	14
39	Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure. <i>ESC Heart Failure</i> , 2020, 7, 3320-3328.	3.1	2
40	Cardiovascular disease and COVID-19: les liaisons dangereuses. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1017-1025.	1.8	27
41	Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction. <i>European Journal of Preventive Cardiology</i> , 2020, , 204748732092761.	1.8	21
42	Lung Ultrasound for Heart Failure Diagnosis in Primary Care. <i>Journal of Cardiac Failure</i> , 2020, 26, 824-831.	1.7	13
43	Highly sensitive troponin T dynamics and prognosis in asymptomatic severe aortic stenosis. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 1065-1066.	0.6	0
44	Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction. <i>Journal of Clinical Medicine</i> , 2020, 9, 831.	2.4	15
45	Rehospitalization burden and morbidity risk in patients with heart failure with mid-range ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 1007-1014.	3.1	14
46	Nepriylsin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study. <i>ESC Heart Failure</i> , 2020, 7, 559-566.	3.1	15
47	Mini Nutritional Assessment Short Form is a morbi-mortality predictor in outpatients with heart failure and mid-range left ventricular ejection fraction. <i>Clinical Nutrition</i> , 2020, 39, 3395-3401.	5.0	21
48	Cardiorenal interaction and heart failure outcomes. A role for insulin-like growth factor binding protein 2?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 835-843.	0.6	5
49	Response. The ST2-SCD score in ambulatory heart failure patients. <i>International Journal of Cardiology</i> , 2020, 300, 207.	1.7	0
50	Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach. <i>Journal of Clinical Medicine</i> , 2020, 9, 1110.	2.4	19
51	Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline. <i>Cardiovascular Diabetology</i> , 2020, 19, 38.	6.8	9
52	Pulmonary hypertension and right ventricular dysfunction in heart failure: prognosis and 15-year prospective longitudinal trajectories in survivors. <i>European Journal of Heart Failure</i> , 2020, 22, 1214-1225.	7.1	17
53	Use of intravenous iron in patients with iron deficiency and chronic heart failure: Real-world evidence. <i>European Journal of Internal Medicine</i> , 2020, 80, 91-98.	2.2	10
54	La fibrosis intersticial miocárdica en la era de la medicina de precisión. El fenotipado basado en biomarcadores para un tratamiento personalizado. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 248-254.	1.2	8

#	ARTICLE	IF	CITATIONS
55	Advanced remote care for heart failure in times of COVID-19 using an implantable pulmonary artery pressure sensor: the new normal. <i>European Heart Journal Supplements</i> , 2020, 22, P29-P32.	0.1	10
56	Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial IRON Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e014254.	3.7	58
57	Destination Therapy with Left Ventricular Assist Devices in Non-transplant Centres: The Time is Right. <i>European Cardiology Review</i> , 2020, 15, e19.	2.2	9
58	Repeat physical stress echocardiography in asymptomatic severe aortic stenosis. <i>Cardiology Journal</i> , 2020, 27, 307-308.	1.2	0
59	Dinámica de troponina T de alta sensibilidad y pronóstico en pacientes con estenosis aórtica grave asintomática. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 1065-1066.	1.2	0
60	Lung ultrasound and biomarkers in primary care: Partners for a better management of patients with heart failure?. <i>Journal of Circulating Biomarkers</i> , 2020, 9, 8-12.	1.3	3
61	Evolución de las causas de muerte de pacientes con insuficiencia cardiaca crónica y función sistólica reducida. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 783-784.	1.2	2
62	Entrenamiento de la musculatura inspiratoria y la electroestimulación muscular funcional en el tratamiento de la insuficiencia cardiaca con función sistólica conservada: estudio TRAINING-HF. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 288-297.	1.2	23
63	Una intervención precoz para reducir reingresos a los 30 días en pacientes ancianos frágiles con insuficiencia cardiaca mantiene su beneficio al año. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 261-263.	1.2	2
64	Razón internacional normalizada y mortalidad de los pacientes con insuficiencia cardiaca y fibrilación auricular tratados con antagonistas de la vitamina K. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 616-624.	1.2	4
65	Mortality and Heart Failure Hospitalizations. The Need for an Exhaustive, Official, and Standardized Registry. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 988-990.	0.6	2
66	Trends in modes of death in heart failure over the last two decades: less sudden death but cancer deaths on the rise. <i>European Journal of Heart Failure</i> , 2019, 21, 1259-1266.	7.1	46
67	Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes. <i>JACC Basic To Translational Science</i> , 2019, 4, 831-840.	4.1	65
68	Determination of HLA-A, -B, -C, -DRB1 and -DQB1 allele and haplotype frequencies in heart failure patients. <i>ESC Heart Failure</i> , 2019, 6, 388-395.	3.1	9
69	Acute-phase dynamics and prognostic value of growth differentiation factor-15 in ST-elevation myocardial infarction. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1093-1101.	2.3	11
70	Usefulness of Right Ventricular to Pulmonary Circulation Coupling as an Indicator of Risk for Recurrent Admissions in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2019, 124, 567-572.	1.6	38
71	A bio-clinical approach for prediction of sudden cardiac death in outpatients with heart failure: The ST2-SCD score. <i>International Journal of Cardiology</i> , 2019, 293, 148-152.	1.7	16
72	Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1751-1759.	1.8	28

#	ARTICLE	IF	CITATIONS
73	Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. <i>Circulation</i> , 2019, 140, 31-41.	1.6	195
74	Heart Failure With Preserved Ejection Fraction Infrequently Evolves Toward a Reduced Phenotype in Long-Term Survivors. <i>Circulation: Heart Failure</i> , 2019, 12, e005652.	3.9	53
75	Functional tricuspid regurgitation and recurrent admissions in patients with acute heart failure. <i>International Journal of Cardiology</i> , 2019, 291, 83-88.	1.7	16
76	Association Between Norepinephrine Levels and Abnormal Iron Status in Patients With Chronic Heart Failure: Is Iron Deficiency More Than a Comorbidity?. <i>Journal of the American Heart Association</i> , 2019, 8, e010887.	3.7	27
77	International Normalized Ratio and Mortality Risk in Acute Heart Failure and Nonvalvular Atrial Fibrillation Patients Receiving Vitamin K Antagonists. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 616-624.	0.6	4
78	Mini nutritional assessment is a better predictor of mortality than subjective global assessment in heart failure out-patients. <i>Clinical Nutrition</i> , 2019, 38, 2740-2746.	5.0	30
79	Mejorar la atención médica mediante un modelo integrado de asistencia para pacientes con cardiopatía isquémica o fibrilación auricular. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 779-780.	1.2	4
80	Limitación al flujo aóreo en pacientes con insuficiencia cardíaca: prevalencia y factores asociados. <i>Medicina Clínica</i> , 2019, 153, 191-195.	0.6	1
81	High-sensitivity troponin T in asymptomatic severe aortic stenosis. <i>Biomarkers</i> , 2019, 24, 334-340.	1.9	10
82	Impact of an integral assistance model between primary care and cardiology on the management of patients with ischemic heart disease or atrial fibrillation. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 103-111.	1.4	4
83	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. <i>International Journal of Cardiology</i> , 2019, 277, 166-172.	1.7	32
84	Improving Medical Attention Through an Integral Care Model for Patients With Ischemic Heart Disease or Atrial Fibrillation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 779-781.	0.6	0
85	Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of Heart Failure With Preserved Ejection Fraction: The TRAINING-HF Trial. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 288-297.	0.6	12
86	An Early Post-discharge Intervention Planned to Reduce 30-day Readmissions in old and Frail Heart Failure Patients Remains Beneficial at 1 Year. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 261-263.	0.6	1
87	Seguimiento a largo plazo de pacientes sintomáticos adultos con miocardiopatía no compactada. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 169-171.	1.2	4
88	Mortalidad y reingresos por insuficiencia cardíaca: la necesidad de un registro oficial completo, abierto y homologable. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 988-990.	1.2	2
89	Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction. <i>International Journal of Cardiology</i> , 2018, 257, 188-192.	1.7	32
90	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure. <i>Circulation</i> , 2018, 137, 286-297.	1.6	157

#	ARTICLE	IF	CITATIONS
91	Impact of a "stent for life"™ initiative on post-ST elevation myocardial infarction heart failure: a 15-year heart failure clinic experience. <i>ESC Heart Failure</i> , 2018, 5, 101-105.	3.1	2
92	Left ventricular ejection fraction in heart failure: a clinician's perspective about a dynamic and imperfect parameter, though still convenient and a cornerstone for patient classification and management. <i>European Journal of Heart Failure</i> , 2018, 20, 433-435.	7.1	16
93	Proteomic signature of circulating extracellular vesicles in dilated cardiomyopathy. <i>Laboratory Investigation</i> , 2018, 98, 1291-1299.	3.7	26
94	Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality. <i>Circulation</i> , 2018, 137, 1320-1330.	1.6	121
95	Barcelona Bio-HF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization. <i>European Journal of Heart Failure</i> , 2018, 20, 938-940.	7.1	20
96	Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patients. <i>European Journal of Heart Failure</i> , 2018, 20, 67-75.	7.1	63
97	sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2309-2320.	2.8	126
98	Letter by Fung et al Regarding Article, "Frailty and Clinical Outcomes in Heart Failure: A Systematic Review and Meta-analysis". <i>Journal of the American Medical Association</i> , 2018, 19, 1143-1146.	2.5	0
99	Impact of Frailty on Mortality and Hospitalization in Chronic Heart Failure: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2018, 7, e008251.	3.7	140
100	ST2 in Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e005582.	3.9	30
101	Circulating monocyte subsets and heart failure prognosis. <i>PLoS ONE</i> , 2018, 13, e0204074.	2.5	8
102	Benzodiazepine Use and Long-Term Mortality in Real-Life Chronic Heart Failure Outpatients: A Cohort Analysis. <i>Psychotherapy and Psychosomatics</i> , 2018, 87, 372-374.	8.8	7
103	Importance of iron deficiency in patients with chronic heart failure as a predictor of mortality and hospitalizations: insights from an observational cohort study. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 206.	1.7	18
104	No need for urgent revisiting of kalaemia levels in guidelines despite use of mineralocorticoid receptor antagonists: bring in more evidence. <i>European Journal of Heart Failure</i> , 2018, 20, 1252-1254.	7.1	5
105	No urgent need for revisiting kalaemia guidelines: rebuttal. <i>European Journal of Heart Failure</i> , 2018, 20, 1256-1256.	7.1	1
106	The Barcelona Bio-HF Calculator. <i>JACC: Heart Failure</i> , 2018, 6, 808-810.	4.1	4
107	Advanced interatrial block predicts new-onset atrial fibrillation and ischemic stroke in patients with heart failure: The "Bayes' Syndrome-HF" study. <i>International Journal of Cardiology</i> , 2018, 271, 174-180.	1.7	71
108	Primary Ventricular Fibrillation in the Primary Percutaneous Coronary Intervention ST-Segment Elevation Myocardial Infarction Era (from the "Codi IAM" Multicenter Registry). <i>American Journal of Cardiology</i> , 2018, 122, 529-536.	1.6	13

#	ARTICLE	IF	CITATIONS
109	ST2 and left ventricular remodeling after ST-segment elevation myocardial infarction: A cardiac magnetic resonance study. <i>International Journal of Cardiology</i> , 2018, 270, 336-342.	1.7	21
110	Dynamic Trajectories of Left Ventricular Ejection Fraction in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 72, 591-601.	2.8	132
111	Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients. <i>BMC Geriatrics</i> , 2018, 18, 109.	2.7	33
112	Telomere attrition in heart failure: a flow-FISH longitudinal analysis of circulating monocytes. <i>Journal of Translational Medicine</i> , 2018, 16, 35.	4.4	6
113	Pulmonary vascular resistance versus pulmonary artery pressure for predicting right ventricular remodeling and functional tricuspid regurgitation. <i>Echocardiography</i> , 2018, 35, 1736-1745.	0.9	6
114	Left Ventricular Ejection Fraction in Heart Failure. <i>European Cardiology Review</i> , 2018, 13, 91.	2.2	0
115	Early Postdischarge STOP-HF-Clinic Reduces 30-day Readmissions in Old and Frail Patients With Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 631-638.	0.6	21
116	The Dynamics of Cardiovascular Biomarkers in non-Elite Marathon Runners. <i>Journal of Cardiovascular Translational Research</i> , 2017, 10, 206-208.	2.4	47
117	Potential role for clinical calibration to increase engagement with and application of home telemonitoring: a report from the HeartCycle programme. <i>ESC Heart Failure</i> , 2017, 4, 66-70.	3.1	2
118	Extracellular vesicles do not contribute to higher circulating levels of soluble <sc>LRP</sc>1 in idiopathic dilated cardiomyopathy. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 3000-3009.	3.6	9
119	Bloodstream Amyloid-beta (1-40) Peptide, Cognition, and Outcomes in Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 924-932.	0.6	12
120	Depression as Measured by PHQ-9 Versus Clinical Diagnosis as an Independent Predictor of Long-Term Mortality in a Prospective Cohort of Medical Inpatients. <i>Psychosomatic Medicine</i> , 2017, 79, 273-282.	2.0	30
121	Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. <i>European Journal of Heart Failure</i> , 2017, 19, 1615-1623.	7.1	149
122	Soluble ST2 for Prognosis and Monitoring in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2389-2392.	2.8	43
123	Heart failure with mid-range ejection fraction: a transition phenotype?. <i>European Journal of Heart Failure</i> , 2017, 19, 1635-1637.	7.1	16
124	The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2128-2136.	2.8	43
125	Reply. <i>European Journal of Heart Failure</i> , 2017, 19, 1736-1736.	7.1	0
126	Serum Nprilysin and Recurrent Admissions in Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	20

#	ARTICLE	IF	CITATIONS
127	Biotherapies and biomarkers for cardiovascular diseases. <i>European Heart Journal</i> , 2017, 38, 1784-1786.	2.2	3
128	Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain). <i>BMJ Open</i> , 2017, 7, e018719.	1.9	40
129	Prognostic Value of New-Generation Troponins in ST-Segment Elevation Myocardial Infarction in the Modern Era: The RUTIASTEMI Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	16
130	Rationale and design of a multicentre, prospective, randomised, controlled clinical trial to evaluate the efficacy of the adipose graft transposition procedure in patients with a myocardial scar: the AGTP II trial. <i>BMJ Open</i> , 2017, 7, e017187.	1.9	9
131	No benefit from the obesity paradox for diabetic patients with heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 851-858.	7.1	49
132	Serum neprilysin and recurrent hospitalizations after acute heart failure. <i>International Journal of Cardiology</i> , 2016, 220, 742-744.	1.7	12
133	Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction?. <i>European Journal of Heart Failure</i> , 2016, 18, 576-576.	7.1	4
134	Impact of diabetes on the predictive value of heart failure biomarkers. <i>Cardiovascular Diabetology</i> , 2016, 15, 151.	6.8	51
135	Weight Loss in Obese Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2016, 5, e002468.	3.7	59
136	Wearable vest for pulmonary congestion tracking and prognosis in heart failure: A pilot study. <i>International Journal of Cardiology</i> , 2016, 215, 77-79.	1.7	12
137	Concentraciones plasmáticas de neprilisina: un nuevo marcador pronóstico en la insuficiencia cardíaca. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 535-536.	1.2	2
138	Neprilysin Plasma Concentrations: A New Prognostic Marker in Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 535-536.	0.6	1
139	Soluble neprilysin retains catalytic activity in heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 684-685.	0.6	23
140	Cinética de la hemoglobina y pronóstico a largo plazo en insuficiencia cardíaca. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 820-826.	1.2	13
141	Neprilisina: indicaciones, expectativas y retos. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 647-649.	1.2	8
142	Neprilysin: Indications, Expectations, and Challenges. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 647-649.	0.6	7
143	Brilliant violet fluorochromes in simultaneous multicolor flow cytometry-fluorescence in situ hybridization measurement of monocyte subsets and telomere length in heart failure. <i>Laboratory Investigation</i> , 2016, 96, 1223-1230.	3.7	3
144	Biomarkers in Heart Failure: ST2. , 2016, , 251-268.		0

#	ARTICLE	IF	CITATIONS
145	Nepriylsin and Natriuretic Peptide Regulation in Heart Failure. <i>Current Heart Failure Reports</i> , 2016, 13, 151-157.	3.3	31
146	Transitions of Care Between Acute and Chronic Heart Failure: Critical Steps in the Design of a Multidisciplinary Care Model for the Prevention of Rehospitalization. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 951-961.	0.6	30
147	Hemoglobin Kinetics and Long-term Prognosis in Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 820-826.	0.6	7
148	First-in-man Safety and Efficacy of the Adipose Graft Transposition Procedure (AGTP) in Patients With a Myocardial Scar. <i>EBioMedicine</i> , 2016, 7, 248-254.	6.1	12
149	The real-life value of ST2 monitoring during heart failure decompensation: impact on long-term readmission and mortality. <i>Biomarkers</i> , 2016, 21, 225-232.	1.9	9
150	Circulating Endothelial Progenitor Cells: Potential Biomarkers for Idiopathic Dilated Cardiomyopathy. <i>Journal of Cardiovascular Translational Research</i> , 2016, 9, 80-84.	2.4	11
151	Prediction of survival and magnitude of reverse remodeling using the ST2-R2 score in heart failure: A multicenter study. <i>International Journal of Cardiology</i> , 2016, 204, 242-247.	1.7	26
152	Can Natriuretic Peptides be Used to Guide Therapy?. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2016, 27, 208-16.	0.7	9
153	Aging and Heart Rate in Heart Failure: Clinical Implications for Long-term Mortality. <i>Mayo Clinic Proceedings</i> , 2015, 90, 765-772.	3.0	12
154	Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score. <i>International Journal of Cardiology</i> , 2015, 184, 337-343.	1.7	92
155	Validaci3n de la Barcelona Bio-Heart Failure Risk Calculator en una cohorte de Boston. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 80-81.	1.2	4
156	Validation of the Barcelona Bio-Heart Failure Risk Calculator in a Cohort From Boston. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 80-81.	0.6	3
157	ST2 Pathogenetic Profile in Ambulatory Heart Failure Patients. <i>Journal of Cardiac Failure</i> , 2015, 21, 355-361.	1.7	31
158	Soluble Nepriylsin Is Predictive of Cardiovascular Death and Heart Failure Hospitalization in Heart Failure Patients. <i>Journal of the American College of Cardiology</i> , 2015, 65, 657-665.	2.8	137
159	Body mass index, body fat, and nutritional status of patients with heart failure: The PLICA study. <i>Clinical Nutrition</i> , 2015, 34, 1233-1238.	5.0	42
160	Morbidity and mortality in systolic heart failure also associated with raised serum nepriylsin levels. Reply. <i>International Journal of Cardiology</i> , 2015, 190, 201.	1.7	0
161	Answer. Reverse remodeling in systolic heart failure. The ST2-R2 score: a puzzle yet to be solved?. <i>International Journal of Cardiology</i> , 2015, 187, 556.	1.7	0
162	Risk Prediction Tools in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 267.	4.1	8

#	ARTICLE	IF	CITATIONS
163	Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Nephilysin vs NT-proBNP. Revista Espanola De Cardiologia (English Ed), 2015, 68, 1075-1084.	0.6	23
164	Prognostic Value and Kinetics of Soluble Nephilysin in Acute Heart Failure. JACC: Heart Failure, 2015, 3, 641-644.	4.1	44
165	Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN) Tj ETQq1 1 0,784314 rgBT /Ove 2.5 97		
166	Long-term Prognostic Value for Patients with Chronic Heart Failure of Estimated Glomerular Filtration Rate Calculated with the New CKD-EPI Equations Containing Cystatin C. Clinical Chemistry, 2014, 60, 481-489.	3.2	28
167	Renal function largely influences Galectin-3 prognostic value in heart failure. International Journal of Cardiology, 2014, 177, 171-177.	1.7	52
168	Educational level and self-care behaviour in patients with heart failure before and after nurse educational intervention. European Journal of Cardiovascular Nursing, 2014, 13, 459-465.	0.9	28
169	Comentarios al análisis de la demanda telefónica en una unidad de insuficiencia cardiaca: motivos de consulta y utilización de recursos. Respuesta. Revista Espanola De Cardiologia, 2014, 67, 158-159.	1.2	0
170	Head-to-Head Comparison of 2 Myocardial Fibrosis Biomarkers for Long-Term Heart Failure Risk Stratification. Journal of the American College of Cardiology, 2014, 63, 158-166.	2.8	222
171	A novel wearable vest for tracking pulmonary congestion in acutely decompensated heart failure. International Journal of Cardiology, 2014, 177, 199-201.	1.7	28
172	Comments on the Analysis of Telephone Calls to a Heart Failure Unit: Reasons for the Call and Resource Use. Response. Revista Espanola De Cardiologia (English Ed), 2014, 67, 158-159.	0.6	0
173	Fragility is a key determinant of survival in heart failure patients. International Journal of Cardiology, 2014, 175, 62-66.	1.7	45
174	Comparison of self-care behaviors of heart failure patients in 15 countries worldwide. Patient Education and Counseling, 2013, 92, 114-120.	2.2	211
175	Depression, antidepressants, and long-term mortality in heart failure. International Journal of Cardiology, 2013, 167, 1217-1225.	1.7	62
176	Quality of life monitoring in ambulatory heart failure patients: temporal changes and prognostic value. European Journal of Heart Failure, 2013, 15, 103-109.	7.1	42
177	Combined Use of the Novel Biomarkers High-Sensitivity Troponin T and ST2 for Heart Failure Risk Stratification vs Conventional Assessment. Mayo Clinic Proceedings, 2013, 88, 234-243.	3.0	57
178	Soluble ST2 Serum Concentration and Renal Function in Heart Failure. Journal of Cardiac Failure, 2013, 19, 768-775.	1.7	87
179	The obesity paradox in heart failure: Is etiology a key factor?. International Journal of Cardiology, 2013, 166, 601-605.	1.7	52
180	Análisis de la demanda telefónica en una unidad de insuficiencia cardiaca: motivos de consulta y utilización de recursos. Revista Espanola De Cardiologia, 2013, 66, 914-915.	1.2	7

#	ARTICLE	IF	CITATIONS
181	Head-to-head comparison of high-sensitivity troponin T and sensitive-contemporary troponin I regarding heart failure risk stratification. <i>Clinica Chimica Acta</i> , 2013, 426, 18-24.	1.1	34
182	Effect of Fragility on Quality of Life in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2013, 112, 1785-1789.	1.6	22
183	Analysis of Telephone Calls to a Heart Failure Unit: Reasons for the Call and Resource Use. <i>Revista Espanola De Cardiología (English Ed)</i> , 2013, 66, 914-915.	0.6	0
184	Statins in heart failure: not yet the end of the story?. <i>European Journal of Heart Failure</i> , 2013, 15, 708-709.	7.1	4
185	Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. <i>European Journal of Heart Failure</i> , 2012, 14, 32-38.	7.1	130
186	Evaluation of a telemedicine system for heart failure patients: feasibility, acceptance rate, satisfaction and changes in patient behavior: results from the CARME (Catalan Remote Management Evaluation) study. <i>European Journal of Cardiovascular Nursing</i> , 2012, 11, 410-418.	0.9	28
187	Comentarios a la guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. Un informe del Grupo de Trabajo del Comité de Guías de Práctica Clínica de la Sociedad Española de Cardiología. <i>Revista Espanola De Cardiología</i> , 2012, 65, 874-878.	1.2	32
188	Statins in Heart Failure: The Paradox Between Large Randomized Clinical Trials and Real Life. <i>Mayo Clinic Proceedings</i> , 2012, 87, 555-560.	3.0	55
189	Desnutrición y pronóstico en insuficiencia cardiaca. <i>Revista Espanola De Cardiología</i> , 2012, 65, 196-197.	1.2	3
190	Punto de corte óptimo de NT-proBNP para el diagnóstico de insuficiencia cardiaca mediante un test de determinación rápida en atención primaria. <i>Revista Espanola De Cardiología</i> , 2012, 65, 613-619.	1.2	31
191	Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. <i>American Heart Journal</i> , 2012, 163, 821-828.	2.7	54
192	Estimated Glomerular Filtration Rate and Prognosis in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1709-1715.	2.8	121
193	Limited Value of Cystatin-C over Estimated Glomerular Filtration Rate for Heart Failure Risk Stratification. <i>PLoS ONE</i> , 2012, 7, e51234.	2.5	14
194	Validación de la versión española del Kansas City Cardiomyopathy Questionnaire. <i>Revista Espanola De Cardiología</i> , 2011, 64, 51-58.	1.2	34
195	Telemonitorización no invasiva en pacientes con insuficiencia cardiaca y servicios de urgencias hospitalarios. Respuesta. <i>Revista Espanola De Cardiología</i> , 2011, 64, 949.	1.2	0
196	Usefulness of Body Mass Index to Characterize Nutritional Status in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2011, 108, 1166-1170.	1.6	56
197	Myostatin serum levels in heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 1379-1379.	7.1	2
198	Mortalidad y causas de muerte en pacientes con insuficiencia cardiaca: experiencia de una unidad especializada multidisciplinaria. <i>Revista Espanola De Cardiología</i> , 2010, 63, 303-314.	1.2	60

#	ARTICLE	IF	CITATIONS
199	Niveles sÃ©ricos de miostatina en insuficiencia cardiaca crÃ³nica. Revista Espanola De Cardiologia, 2010, 63, 992-996.	1.2	17
200	Obesidad y pronÃ³stico a largo plazo en la insuficiencia cardiaca: la paradoja continÃ©a. Revista Espanola De Cardiologia, 2010, 63, 1210-1212.	1.2	10
201	Respuesta. Revista Espanola De Cardiologia, 2008, 61, 217-218.	1.2	0
202	Respuesta. Revista Espanola De Cardiologia, 2008, 61, 654.	1.2	1
203	Estimated creatinine clearance: a determinant prognostic factor in heart failure. Medicina ClÃ©nica, 2008, 131, 47-51.	0.6	10
204	Patients' Self-Care Improvement with Nurse Education Intervention in Spain Assessed by the European Heart Failure Self-Care Behaviour Scale. European Journal of Cardiovascular Nursing, 2008, 7, 16-20.	0.9	37
205	Does Heart Failure Therapy Differ According to Patient Sex?. Clinical Cardiology, 2007, 30, 301-305.	1.8	3
206	Sex and age differences in fragility in a heart failure population. European Journal of Heart Failure, 2005, 7, 798-802.	7.1	57
207	Patient's Education by Nurse: What We Really do Achieve?. European Journal of Cardiovascular Nursing, 2005, 4, 107-111.	0.9	42
208	Nurse Evaluation of Patients in a New Multidisciplinary Heart Failure Unit in Spain. European Journal of Cardiovascular Nursing, 2004, 3, 61-69.	0.9	33
209	Usefulness of hospital admission risk stratification for predicting nonfatal acute myocardial infarction or death six months later in unstable angina pectoris. American Journal of Cardiology, 1999, 84, 963-969.	1.6	21
210	Six-month outcome in unstable angina patients without previous myocardial infarction according to the use of tertiary cardiologic resources. Journal of the American College of Cardiology, 1999, 34, 1947-1953.	2.8	12
211	Six-Month Outcome in Patients With Myocardial Infarction Initially Admitted to Tertiary and Nontertiary Hospitals fn1fn1This project was funded by Grant 92/0009 from the Fondo de InvestigaciÃ³n Sanitaria, Madrid and by Grant CIRIT/SGR 9500167 from the Generalitat de Catalunya, Barcelona, Spain. fn2fn2To discuss this article on-line, visit the ACC Home Page at www.acc.org/members and click on the JACC Forum. Journal of the American College of Cardiology, 2007, 39, 1107-1108.	2.8	55
212	Biomarkers in Heart Failure with Preserved Ejection Fraction. Cardiac Failure Review, 0, 8, .	3.0	16